Incidence de la dépression résistante lors du premier épisode dépressif

Auteur/ices

  • Maroua Said Public Mental Health Establishment in Marne (France).
  • Rania Hosni Psychiatry Department A, Razi hospital, Tunis, Tunisia
  • Hend Jemli Psychiatry Department A, Razi hospital, Tunis, Tunisia
  • Yosra Zgueb Psychiatry Department A, Razi hospital, Tunis, Tunisia
  • Uta Ouali Psychiatry Department A, Razi hospital, Tunis, Tunisia
  • Haifa Zalila Outpatient Psychiatry Department, Razi Hospital, Tunisia
  • Fethi Nacef Psychiatry Department A, Razi hospital, Tunis, Tunisia
  • Rabaa Jomli Psychiatry Department A, Razi hospital, Tunis, Tunisia

Mots-clés :

dépression résistante, Incidence, fluoxetine, sertraline

Résumé

Introduction : La dépression représente un problème majeur de santé publique. Le préjudice de cette maladie, est dû pour une part importante à la résistance, qui peut aboutir à la chronicité. Objectif : Estimer l’incidence de la dépression résistante au cours d’un premier épisode dépressif majeur et rechercher les facteurs sociodémographiques et cliniques associés à cette résistance. Méthodes : Une étude descriptive longitudinale et prospective a été menée, auprès des consultants à l’hôpital Razi, pour un premier épisode dépressif majeur. Les patients inclus dans l’étude ont été mis sous traitement antidépresseur, à base de fluoxétine ou sertraline. La première phase de traitement a consisté de suivre la réponse au premier antidépresseur avec un contrôle tous les quinze jours et une augmentation de la dose jusqu’à la dose maximale. En l’absence de réponse au premier antidépresseur, un swich pour le deuxième antidépresseur est fait avec contrôle tous les quinze jours et augmentation de la dose jusqu’à la dose maximale. Les participants ont été suivis régulièrement jusqu’à l’obtention d’une réponse thérapeutique ou bien la réunion des critères d’une dépression résistante. Résultats : Notre étude a intéressé 82 patients, ayant un âge moyen de 44,5±11,1 ans. Des antécédents familiaux de trouble dépressif ont été notés chez 17,3% des patients, de trouble bipolaire chez 11,1%, de trouble psychotique chez 13,6%, et de trouble anxieux chez 14,9%, alors que 14,7% avaient un trouble de la personnalité. Chez notre population, le taux de réponse au premier antidépresseur était de 47,2%. Le taux de réponse au deuxième antidépresseur était de 57,1%. L’incidence de la dépression résistante, chez notre population, était de 19,4%. Une association statistiquement significative entre la dépression résistante et la présence d’antécédents familiaux de psychose d’une part, et d’autre part avec les comorbidités respiratoires chroniques a été retrouvée. Conclusion: L’incidence de la dépression résistante dans ce travail se situe dans la limite inférieure des chiffres de prévalence de la résistance rapportés dans la littérature. Les facteurs cliniques prédictifs de résistance contribuent probablement à identifier ces patients. Dans le futur, l’analyse génotypique permettra probablement une évaluation plus sensible et plus précoce de la réponse thérapeutique.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Références

Depression [WWW Document]. WHO, 2019. Accessed December 30, 2019. https://www.who.int/news-room/fact-sheets/detail/depression

Richards D. Prevalence and clinical course of depression: a review. Clin Psychol Rev. 2011;31 (7):1117-1125. doi:10.1016/j.cpr.2011.07.004

Rao D, Xu G, Lu Z, Liang H, Lin K, Tang M. Comparative Study of Cognitive Function Between Treatment-Resistant Depressive Patients and First-Episode Depressive Patients. Neuropsychiatr Dis Treat. 2019;15:3411-3417. doi:10.2147/NDT.S226405

Li G, Fife D, Wang G, et al. All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. Ann Gen Psychiatry. 2019;18:23. doi:10.1186/s12991-019-0248-0

McCrone P, Rost F, Koeser L, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health Abingdon Engl. 2018;27 (6):567-573. doi:10.1080/09638237.2017.1417562

Sussman M, O’sullivan AK, Shah A, Olfson M, Menzin J. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. J Manag Care Spec Pharm. 2019;25 (7):823-835. doi:10.18553/jmcp.2019.25.7.823

Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16 (5):370-377.

Demyttenaere K, Van Duppen Z. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol. 2019;22 (2):85-92. doi:10.1093/ijnp/pyy052

Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68 (7):1062-1070. doi:10.4088/jcp.v68n0713

Kim SYH, De Vries RG, Peteet JR. Euthanasia and Assisted Suicide of Patients With Psychiatric Disorders in the Netherlands 2011 to 2014. JAMA Psychiatry. 2016;73 (4):362-368. doi:10.1001/jamapsychiatry.2015.2887

Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. WORLD SCIENTIFIC; 2010. doi:10.1142/7468

Thienpont L, Verhofstadt M, Van Loon T, Distelmans W, Audenaert K, De Deyn PP. Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open. 2015;5 (7):e007454. doi:10.1136/bmjopen-2014-007454

Scherrer JF, Chrusciel T, Garfield LD, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry J Ment Sci. 2012;200 (2):137-142. doi:10.1192/bjp.bp.111.096479

Ruhé HG, van Rooijen G, Spijker J, Peeters FPML, Schene AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137 (1-3):35-45. doi:10.1016/j.jad.2011.02.020

Malhi GS, Das P, Mannie Z, Irwin L. Treatment-resistant depression: problematic illness or a problem in our approach? Br J Psychiatry J Ment Sci. 2019;214 (1):1-3. doi:10.1192/bjp.2018.246

Fekadu A, Wooderson S, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70 (2):177-184. doi:10.4088/jcp.08m04309

Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37 (2):134-145. doi:10.1002/da.22968

Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2019;245:626-636. doi:10.1016/j.jad.2018.11.038

Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19 (2):179-200. doi:10.1016/s0193-953x (05)70283-5

Friedman ES, Anderson I. Handbook of Depression: Second Edition. Springer Healthcare Communications; 2014. doi:10.1007/978-1-907673-79-5

Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry Rev Can Psychiatr. 2010;55 (3):126-135. doi:10.1177/070674371005500303

Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry Rev Can Psychiatr. 2014;59 (7):349-357. doi:10.1177/070674371405900702

Sackeim HA, Aaronson ST, Bunker MT, et al. The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). J Psychiatr Res. 2019;113:125-136. doi:10.1016/j.jpsychires.2019.03.021

Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons; 2015.

Targum SD. Identification and treatment of antidepressant tachyphylaxis. Innov Clin Neurosci. 2014;11 (3-4):24-28.

Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008;42 (9):751-762. doi:10.1080/00048670802277206

Kocsis JH, Gelenberg AJ, Rothbaum B, et al. Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord. 2008;110 (1-2):55-61. doi:10.1016/j.jad.2008.01.002

Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P. Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35 (3):220-228. doi:10.1002/da.22705

Sackeim HA, Roose SP, Lavori PW. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biol Psychiatry. 2006;59 (6):483-492. doi:10.1016/j.biopsych.2005.08.033

Kautzky A, Dold M, Bartova L, et al. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139 (1):78-88. doi:10.1111/acps.12959

Gronemann FH, Jorgensen MB, Nordentoft M, Andersen PK, Osler M. Socio-demographic and clinical risk factors of treatment-resistant depression: A Danish population-based cohort study. J Affect Disord. 2020;261:221-229. doi:10.1016/j.jad.2019.10.005

van Belkum SM, Geugies H, Lysen TS, et al. Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety. J Clin Psychiatry. 2018;79 (1):17m11475. doi:10.4088/JCP.17m11475

Tabeleão V, Tomasi E, de Avila Quevedo L. A Randomized, Controlled Trial of the Effectiveness of a Psychoeducational Intervention on Family Caregivers of Patients with Mental Disorders. Community Ment Health J. 2018;54 (2):211-217. doi:10.1007/s10597-017-0126-7

van Wijngaarden B, Schene AH, Koeter MWJ. Family caregiving in depression: impact on caregivers’ daily life, distress, and help seeking. J Affect Disord. 2004;81 (3):211-222. doi:10.1016/S0165-0327 (03)00168-X

Francesca MM, Efisia LM, Alessandra GM, Marianna A, Giovanni CM. Misdiagnosed hypomanic symptoms in patients with treatment-resistant major depressive disorder in Italy: results from the improve study. Clin Pract Epidemiol Ment Health CP EMH. 2014;10:42-47. doi:10.2174/1745017901410010042

Meyer TD, Schrader J, Ridley M, Lex C. The Hypomania Checklist (HCL) - systematic review of its properties to screen for bipolar disorders. Compr Psychiatry. 2014;55 (5):1310-1321. doi:10.1016/j.comppsych.2014.03.002

Rybakowski JK, Dudek D, Pawlowski T, Lojko D, Siwek M, Kiejna A. Use of the Hypomania Checklist-32 and the Mood Disorder Questionnaire for detecting bipolarity in 1051 patients with major depressive disorder. Eur Psychiatry J Assoc Eur Psychiatr. 2012;27 (8):577-581. doi:10.1016/j.eurpsy.2010.12.001

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. doi:10.1136/jnnp.23.1.56

Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract J R Coll Gen Pract. 2013;63 (617):e852-858. doi:10.3399/bjgp13X675430

Chiarotti F, Viglione A, Giuliani A, Branchi I. Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study. Transl Psychiatry. 2017;7 (3):e1066. doi:10.1038/tp.2017.35

Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68 Suppl 8:17-25.

Saveanu R, Etkin A, Duchemin A-M, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015;61:1-12. doi:10.1016/j.jpsychires.2014.12.018

Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67 (12):1836-1855. doi:10.4088/jcp.v67n1203

Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull. 1992;28 (3):253-256.

Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58 (1):16-21. doi:10.4088/jcp.v58n0103

Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103 (1):66-72. doi:10.1034/j.1600-0447.2001.00148.x

Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31 (4):512-516. doi:10.1097/JCP.0b013e3182228619

Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9 (6):449-459. doi:10.1007/s11920-007-0061-3

Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996;57 (2):67-71.

Fife D, Feng Y, Wang MY-H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277-283. doi:10.1016/j.psychres.2017.03.006

Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PloS One. 2013;8 (10):e76882. doi:10.1371/journal.pone.0076882

Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol. 2009;24 (1):1-18. doi:10.1097/YIC.0b013e32831db2d7

Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43 (5):503-511. doi:10.1016/j.jpsychires.2008.07.002

Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157 (9):1445-1452. doi:10.1176/appi.ajp.157.9.1445

Husain MM, Rush AJ, Wisniewski SR, et al. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry. 2009;70 (2):185-195. doi:10.4088/jcp.07m03571

Serretti A, Calati R, Oasi O, De Ronchi D, Colombo C. Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry. 2007;6:5. doi:10.1186/1744-859X-6-5

Rihmer Z, Dome P, Gonda X. Antidepressant response and subthreshold bipolarity in “unipolar” major depressive disorder: implications for practice and drug research. J Clin Psychopharmacol. 2013;33 (4):449-452. doi:10.1097/JCP.0b013e318299d2d5

Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med. 2009;1 (10):102. doi:10.1186/gm102

Sugawara H, Murata Y, Ikegame T, et al. DNA methylation analyses of the candidate genes identified by a methylome-wide association study revealed common epigenetic alterations in schizophrenia and bipolar disorder. Psychiatry Clin Neurosci. 2018;72 (4):245-254. doi:10.1111/pcn.12645

Green EK, Grozeva D, Jones I, et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry. 2010;15 (10):1016-1022. doi:10.1038/mp.2009.49

Dudek D, Siwek M, Zielińska D, Jaeschke R, Rybakowski J. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review. J Affect Disord. 2013;144 (1-2):112-115. doi:10.1016/j.jad.2012.06.014

Masson E. Prévalence de l’hypomanie dans les dépressions majeures récurrentes ou résistantes : enquêtes Bipolact. EM-Consulte. Accessed October 14, 2021. https://www.em-consulte.com/article/200588/prevalence-de-lhypomanie-dans-les-depressions-maje

Perlis RH. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry. 2013;74 (1):7-14. doi:10.1016/j.biopsych.2012.12.007

Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry. 1998;59 (12):669-675. doi:10.4088/jcp.v59n1205

Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163 (1):28-40. doi:10.1176/appi.ajp.163.1.28

Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37 (6):518-522. doi:10.1016/S0033-3182 (96)71515-3

Kool S, Schoevers R, de Maat S, et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord. 2005;88 (3):269-278. doi:10.1016/j.jad.2005.05.017

Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65 (8):870-880. doi:10.1001/archpsyc.65.8.870

Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000; (4):CD001312. doi:10.1002/14651858.CD001312

Krishnan KRR. Comorbidity and depression treatment. Biol Psychiatry. 2003;53 (8):701-706. doi:10.1016/s0006-3223 (02)01787-0

Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33 (2):190-201. doi:10.1016/S0033-3182 (92)71995-1

Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. 2005;2 (2):233-241.

Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm. 2016;2016:3690628. doi:10.1155/2016/3690628

Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors Associated with Depression in COPD: A Multicenter Study. Lung. 2016;194 (3):335-343. doi:10.1007/s00408-016-9862-7

Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics. 2012;53 (1):75-80. doi:10.1016/j.psym.2011.07.009

Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39 (1):24-29. doi:10.1016/S0033-3182 (98)71377-5

Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol. 1993;8 (3):197-202. doi:10.1097/00004850-199300830-00010

Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56 (6):229-237.

Fichiers supplémentaires

Publiée

2023-08-24

Numéro

Rubrique

Articles originaux